Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.

Vedolizumab does not promote malignancies in IBD patients

08 Jan 2020

Use of vedolizumab for inflammatory bowel disease (IBD) does not contribute to an increased incidence of malignancies, with data from the GEMINI LTS study showing that the rate is similar in groups of patients who received the 4- and 8-weekly infusion regimens.

The current analysis included 1,785 IBD patients (mean age, 39.5 years; 49 percent female) with ≥1 year of follow-up after vedolizumab initiation. Of these, 1,034 had Crohn’s disease (CD) and 751 had ulcerative colitis (UC).  

In 5,670 patient‐years of included vedolizumab exposure, 31 patients (mean age, 51.2 years; 45 percent female) developed malignancies, including 17 with CD and 14 with UC.

Prior use of anti‐TNFα therapy in the group that developed malignancies was documented in 65 percent of CD patients and 57 percent of UC patients; the corresponding proportions in the LTS study were 62 percent and 43 percent.

Researchers indirectly standardized the number of patients experiencing malignancies in the LTS study against the number expected using age- and sex-specific rates in IBD patients from Optum's Clinformatics Data Mart (CDM) database and found that the numbers did not significantly differ (31 vs 29; ratio of observed to expected events, 1.08, 95 percent confidence interval [CI], 0.73–1.53; p=0.71). The most common sites of malignancies were renal and bladder (n=6), lower gastrointestinal (GI) tract (n=5), and respiratory tract (n=4).

In the postmarketing setting, 293 patients reported 299 malignancies (including malignancies within 1 year after vedolizumab initiation) in about 208,050 patient-years of vedolizumab exposure. Lower GI malignancies were most common (n=59).

Despite the presence of limitations, the existing data revealed no evidence of any significant increase in incidence of malignancy in patients with IBD receiving vedolizumab, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.